RNACCartesian Therapeutics, Inc.vs its industry peers
A metric-by-metric comparison of Cartesian Therapeutics, Inc. against SIC 2834 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Company | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RNACThis | $242M#6 | — | — | 605.5x#8 | -99.0%#8 | -68.3%#13 | -35851.3%#8 | — | — | — | — | — |
| CUE | $260M#2 | — | 112.3x#11 | 9.4x#6 | 195.7%#2 | 34.6%#5 | -96.7%#5 | -1151.6%#11 | — | — | 61.7%#3 | — |
| GLSI | $255M#3 | — | 81.8x#10 | — | — | -11.2%#10 | — | -621.1%#10 | — | — | — | — |
| FHTX | $250M#4 | — | — | 8.1x#5 | 36.8%#4 | 14.2%#8 | -279.5%#6 | — | — | — | -13.4%#5 | — |
| AKBA | $244M#5 | — | 9.8x#9 | 1.0x#3 | 47.5%#3 | 92.4%#3 | 9.9%#3 | -21.2%#5 | — | — | — | — |
| ALXO | $241M#7 | — | 1.8x#7 | — | — | 24.6%#6 | — | -74.7%#7 | -84.4%#1 | — | — | — |
| WHWK | $235M#8 | — | 1.3x#3 | 32.9x#7 | -72.5%#7 | 67.7%#4 | -1601.1%#7 | -11.3%#4 | — | — | 110.2%#2 | — |
| NATR | $232M#9 | 13.2x#1 | 1.7x#6 | 0.5x#1 | 5.7%#5 | 153.7%#1 | 5.2%#4 | 14.3%#2 | — | 9#1 | -19.9%#6 | — |
| ZNTL | $221M#10 | — | 1.5x#5 | — | -100.0%#9 | 17.4%#7 | — | -95.4%#8 | — | — | 116.9%#1 | — |
| SIGA | $220M#11 | — | 1.3x#4 | 2.3x#4 | -31.8%#6 | -60.7%#12 | 25.1%#2 | 14.1%#3 | — | — | -57.8%#8 | 19.6%#1 |
| KROS | $220M#12 | — | 0.8x#2 | 0.9x#2 | 6775.0%#1 | 146.4%#2 | 27.7%#1 | 33.2%#1 | — | — | -28.9%#7 | — |
| ELDN | $215M#13 | — | 6.5x#8 | — | — | -26.1%#11 | — | -138.2%#9 | — | — | — | — |
| BRVE | $2.6B#1 | — | — | — | — | — | — | — | — | — | — | — |
| NKTX | $201M#14 | — | 0.8x#1 | — | — | 4.3%#9 | — | -42.0%#6 | — | — | 45.8%#4 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. This table timed out mid-build, so it covers part of the group; ranks are within the rows shown and it fills in shortly. Table built 2026-09-17.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice